Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank29
3Y CAGR-22.8%
5Y CAGR-21.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-22.8%/yr
vs -23.1%/yr prior
5Y CAGR
-21.6%/yr
Consistent
Acceleration
+0.3pp
Accelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 6.35% |
| 2024 | -17.94% |
| 2023 | 16.72% |
| 2022 | 13.80% |
| 2021 | 28.41% |
| 2020 | 21.51% |
| 2019 | 66.31% |
| 2018 | 39.40% |
| 2017 | 155.43% |
| 2016 | 81.23% |